key: cord-0871341-ehe857e6 authors: Kaneko, Shun; Kurosaki, Masayuki; Sugiyama, Toru; Takahashi, Yuka; Yamaguchi, Yoshimi; Nagasawa, Masayuki; Izumi, Namiki title: The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination date: 2021-08-05 journal: J Med Virol DOI: 10.1002/jmv.27231 sha: b040345c3febb850d41d5d7d70b672ae57c984ac doc_id: 871341 cord_uid: ehe857e6 Vaccination for SARS‐CoV‐2 is necessary to overcome coronavirus disease 2019 (COVID‐19). However, the time‐dependent vaccine‐induced immune response is not well understood. This study aimed to investigate the dynamics of SARS‐CoV‐2 antispike immunoglobulin G (IgG) response. Medical staff participants who received two sequential doses of the BNT162b2 vaccination on days 0 and 21 were recruited prospectively from the Musashino Red Cross Hospital between March and May 2021. The quantitative antispike receptor‐binding domain (RBD) IgG antibody responses were measured using the Abbott SARS‐CoV‐2 IgGII Quant assay (cut off ≥50 AU/ml). A total of 59 participants without past COVID‐19 history were continuously tracked with serum samples. The median age was 41 (22–75) years, and 14 participants were male (23.7%). The median antispike RBD IgG and seropositivity rates were 0 (0–31.1) AU/ml, 0.3 (0–39.5) AU/ml, 529.1 (48.3–8711.4) AU/ml, 18,836.9 (742.2–57,260.4) AU/ml, and 0%, 0%, 98.3%, and 100% on days 0, 3, 14, and 28 after the first vaccination, respectively. The antispike RBD IgG levels were significantly increased after day 14 from vaccination (p < 0.001) The BNT162b2 vaccination led almost all participants to obtain serum antispike RBD IgG 14 days after the first dose. SARS-CoV2 has an infection pattern with invasion into cells expressing angiotensin-converting enzyme type 2 (ACE2) via S protein. SARS-CoV-2 adheres to target cells by fusing ACE2 with the receptor-binding domain (RBD) region located at the tip of the S protein. 12 The representative Pfizer vaccines were known as BNT162b1 and BNT162b2. The former is designed for the RBD region only, and the latter is designed for the entire sequence of the S protein. 13 Early studies on mRNA vaccines from BioNTech/Pfizer and Moderna showed high efficacy and safety. 9, 10 Also, more promising reports on the effectiveness of the vaccines after completing the full vaccination schedule (prime and boost dose) have been published. [14] [15] [16] The vaccine's effectiveness in preventing death from COVID-19 was 72% for days 14-20 after the first dose. 14 Although high efficiency was observed in clinical trials and initial real-situation vaccinations, the first published studies with Pfizer-BioNTech mRNA vaccines have reported weaker immune responses and a higher number of nonresponders among older people after the single and second dose of the BNT162b2 vaccine. 17, 18 Conversely, current vaccines cause an immune response to viral spike antigens, antispike antibodies, associated with neutralizing activity. [19] [20] [21] The antibodies against RBD of SARS-CoV-2 protein have been shown to inhibit interactions with ACE2, suggesting that RBD is an attractive target and marker for vaccination. However, the characteristics and the dynamics have not been well clarified. The measurement of the dynamics of the immune response may provide a potential surrogate marker of protection. In the present study, we analyzed the dynamics of quantitative SARS-CoV-2 antispike RBD IgG response to BNT162b2 mRNA vaccination. The Pfizer-BioNTech BNT162b2 vaccine 9 was predominately provided to the medical staff at an acute hospital in Japan. The medical staff vaccination program started in March 2021 at the Musashino Red Cross Hospital. The protocol was a two-step vaccination with a procedure in which the first vaccination is followed by a second vaccination with the same dose 21 days later as previously reported. 9 The medical staff was invited to participate to take a blood test at least once were not included in this study. A total of 59 participants with every serum sample were tested for serum antibody assay. This study provides evidence regarding the dynamics of quantitative SARS-CoV-2 antispike RBD IgG response to BNT162b2 mRNA vaccination. BNT162b2 mRNA vaccination led the antibodies of almost all participants to seropositive after the first vaccination. In this study with observation for 28 days, the median RBD IgG levels on day 28 were the highest (18,836.9 (742.2-57,260.4), p < 0.001). Conversely, the IgG levels on day 3 were not significantly changed from day 0 (p = 0.82). This result supported the previous report that estimated the effectiveness in preventing death from COVID-19 for days 14-20 after the first vaccination. 14 In terms of characteristics of participants, there were no significant differences when compared with gender or age with IgG procedure. Muller et al. 17 reported that background differences between the antibody responses were raised after the first and second BNT162b2 vaccinations, at particular lower frequencies of neutralizing antibodies in the elderly group (>80 years of age). As a premise, physical binding such as RBD and neutralization assays are different and cannot be compared. If we had enough same-generation participants, referential data regarding RBD might have been given. Our cohort did not include such elderly groups, and most of the participants (56/59) were younger (<60 years of age). Although there was no significant difference between those under and over 50 years old, the antibody titer of under 50 years old tended to be numerically higher on days 14 and 28. Such an analysis including more older people is also expected. This study has certain novel points. First, we were tracking the serum IgG data of the same person over time. Furthermore, our tracking data included the day 3 point. Previously, we investigated the plasma anti-SARS-CoV-2 antibody for the patients infected with COVID-19. 23 We could exclude the fact that every participant was either infected or was in the process of producing antibodies by measuring RBD antibody titers on days 0 and 3 after the first vaccination and the serum IgG against SARS-CoV-2 N protein. Given that the degree of qualitative antispike RBD results is a surrogate marker of protection against infection, other endpoints of interest such as hospitalization and death remain unclear. In conclusion, BNT162b2 mRNA vaccination led to almost 100% Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis World Health Organization. Coronavirus disease (COVID-19) Immunological mechanisms of vaccine-induced protection against COVID-19 in humans Amplifying RNA vaccine development Recent advances in mRNA vaccine technology Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine SARS-CoV-2 vaccine development: current status SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor The dawn of mRNA vaccines: the COVID-19 case BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Robust neutralizing antibodies to SARS-CoV-2 infection persist for months An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. medRxiv Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort The authors appreciate the cooperation of the COVID-19 countermeasure team, support staff, and their families at Musashino Red Cross Hospital. The authors declare that there are no conflict of interests. http://orcid.org/0000-0003-2660-6580Namiki Izumi https://orcid.org/0000-0002-0055-8229